• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Arctic Bioscience AS: Arctic Bioscience invited to present at the Glaucoma 360 New Horizons Forum

Arctic Bioscience
Read the release

Arctic Bioscience are pleased to announce that we have been invited to present at the Glaucoma 360 New Horizons Forum in San Francisco on January 30th 2026, in the session `The Perfect Dose: Innovating Drugs and Drug Delivery'.

Our Medical Director, Runhild Gammelsæter, will be presenting our latest pipeline project, ABS403, with the aim to promote resolution of inflammation and support neuroprotection in glaucoma. This eye disease does not currently have a cure and leads to blindness.

The project was initiated based on encouraging clinical signals from a pilot study in glaucoma (POAG).

As we prepare for the next stages, we are actively seeking partners and investors to join us in advancing ABS403 into further clinical development.

Read more about the event: https://glaucoma360.org/

Read more about the promising pilot trial by Luo et al: https://doi.org/10.1007/s10792-025-03693-1